Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera

We report a 55 year old woman with post-ET PV for 12 years, who experienced resolution of severe constitutional symptoms within 3 days, a marked reduction in splenomegaly and a rapid decline in the JAK2V617F allele burden during combination therapy with interferon-alpha2a and ruxolitinib. Within 4 w...

Descripción completa

Detalles Bibliográficos
Autores principales: Bjørn, M.E., de Stricker, K., Kjær, L., Ellemann, K., Hasselbalch, H.C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216335/
https://www.ncbi.nlm.nih.gov/pubmed/25379406
http://dx.doi.org/10.1016/j.lrr.2014.05.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216335/
https://www.ncbi.nlm.nih.gov/pubmed/25379406
http://dx.doi.org/10.1016/j.lrr.2014.05.003

Ejemplares similares